However, the efficacy and benefit of BTKis for this type of DLBCL need to be further analysed using a larger sample size.<h4>Conclusion</h4>This study suggests that newly diagnosed DLBCL patients with MYD88<sup>mut</sup> and/or CD79B<sup>mut</sup> may benefit from BTKis according to real-world clinical data. Here, MYD88 is linked to diffuse large B-cell lymphoma.